Use of biomarkers in cancer research and treatment
Biomarkers – biological tests that give key information about a patient – have a huge role to play in the future of precision medicine which is why ten leading institutions, charities, stakeholder groups and life-science companies have developed a new set of 13 consensus statements aiming to drive wider use of biomarkers and more effective use of precision medicine for cancer patients.
The consensus statements, as detailed below, call for an acceleration of research to identify new biomarkers for cancer, and for changes to regulations and funding to ensure biomarker tests and molecular profiling of cancers are used more routinely as part of NHS care.
Download the consensus statements
Our research on biomarkers